Alterity Therapeutics (FRA:PBN) ROCE %: 0.00% (As of Dec. 2025)


FRA:PBN Alterity Therapeutics Ltd FRA:PBN
27 GF Score
Price €0.34
View Full Analysis

What is Alterity Therapeutics ROCE %?

Alterity Therapeutics FRA:PBN +0.60% 27 ROCE % is 0.00% as of Dec. 2025. GuruFocus rates FRA:PBN with a GF Score™ of 27/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Alterity Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2025 was 0.00%.

Alterity Therapeutics  (FRA:PBN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Alterity Therapeutics ROCE % Related Terms

Alterity Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics ROCE % Chart

Alterity Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -78.69 -46.81 -47.04 -105.20 -42.80

Alterity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:PBN
27GF Score
Alterity Therapeutics Ltd FRA:PBN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics ROCE % Calculation

Alterity Therapeutics's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-6.962/( ( (11.859 - 3.315) + (25.98 - 1.995) )/ 2 )
=-6.962/( (8.544+23.985)/ 2 )
=-6.962/16.2645
=-42.80 %

Alterity Therapeutics's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=0/( ( (0 - 0) + (32.298 - 1.467) )/ 1 )
=0/( ( 0 + 30.831 )/ 1 )
=0/30.831
=0.00 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Alterity Therapeutics (FRA:PBN) has a ROCE % of 0.00% as of Dec. 2025.
Is Alterity Therapeutics' ROCE % too high?
Alterity Therapeutics' current ROCE % is 0.00%. Overall, Alterity Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' ROCE % compare to VRTX and REGN?
Alterity Therapeutics' ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Alterity Therapeutics's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (FRA:PBN) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Alterity Therapeutics' overall GF Score™ is 27/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Alterity Therapeutics (FRA:PBN), the current ROCE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterity Therapeutics Business Description

Other Exchanges ATHE:USAATH:Australia
Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
27GF Score

Get the complete analysis for FRA:PBN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.34
Price